Letter from Stephen L. Holst (Director of Regulatory Affairs, Hyland Therapeutics Division, Travenol Laboratories Inc.) to Elaine C. Esber M.D (Director, Office of Biologics Research and Review, Division of Product Certification, Center for Drugs and Biologics). Mentions Hyland's introduction of heat treatment and the market withdrawal of non-treated antihemophilic factor.